T

he Food and Drug Administration told Amicus Therapeutics (FOLD) that it lacks sufficient clinical data on an experimental treatment for Pompe disease to submit a marketing application, the company said Monday.

The regulatory setback means Amicus will have to wait until 2019 to seek U.S. approval for the drug, called AT-GAA — after clinical data in additional Pompe patients are collected.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy